The peripheral blood mononuclear cell (PBMC)-based assay provides improved consistency and robustness for measuring antibody-dependent cellular cytotoxicity (ADCC). The assays provide ADCC-qualified PBMC effector cells and a choice of popular target cells expressing a HiBiT fusion protein. Upon target-cell killing, a bright luminescent signal is generated. The bioassay is simple, homogenous, highly sensitive and provides a robust assay window. It demonstrates antibody potency comparable with the ADCC Reporter Bioassay in ADCC bridging studies.